Annual Report 2023
Department of Thoracic Oncology
Koichi Goto, Kiyotaka Yoh, Shingo Matsumoto, Yoshitaka Zenke, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Eri Sugiyama, Hibiki Udagawa, Yosuke Kagawa, Yu Tanaka, Yuki Kato, Yuji Uehara, Haruka Fujioka, Tsuyoshi Hirata, Chin Haruka, Hironori Kobayasi, Hiroki Kontani, (Seiji Niho, Keisuke Kirita, Kaname Nosaki, Yuji Shibata, Masanobu Okahisa)
Introduction
The Department of Thoracic Oncology provides care for patients with primary lung cancer, mediastinal tumors, and pleural tumors. The department aims to provide the highest quality treatment and establish new effective therapies against lung cancer and other thoracic malignancies through innovative clinical and translational research. To assist our patients through multidisciplinary care, our staff members work closely with thoracic surgeons, radiation oncologists, pathologists, pharmacists, clinical research coordinators, and psychiatrists with expertise in these areas. Moreover, residents and trainees from other institutions have joined the Thoracic Oncology Program.
The Team and What We Do
Our outpatient clinic, managed by staff members and senior residents, is open from Monday to Friday to examine all newly referred patients and evaluate returning patients. Returning patients also receive oral or intravenous chemotherapy in the Ambulatory Care Center. Bronchoscopy with EBUS for diagnosis is performed from Monday to Thursday afternoon. Fluoroscopic-CT guided needle lung biopsies are carried out on Tuesday afternoon. We use approximately 50-60 beds for patient management mainly in 8F, 6A, 6B, and 5A wards.
Case conferences on thoracic surgery and medical oncology are scheduled on Tuesday evenings and Wednesday evenings, respectively. The staff members and residents of the division participate in a journal club on Monday and Wednesday mornings. During monthly meetings with physicians in private hospitals, the staff and residents teach reading methods for chest X-rays and CT images.
Table 2. Type of treatment for Lung Cancer
Research Activities
Our research activities are focused on three areas: 1) the development of new and effective diagnosis and treatment modalities in lung cancer; 2) collaborative studies with the Research Center for Innovative Oncology in the following areas: detection of biomarkers for the treatment of advanced lung cancer; development of new diagnostic methods of rare driver genomic alteration for lung cancer; correlation between genomic abnormalities and clinical characteristics and treatment in lung cancer; correlation between pathological features and sensitivity of treatments in lung cancer; and 3) translational research from bench to bedside or from bed-side to bench for the development of innovative treatment strategies in lung cancer.
In particular, high-spec genomic analysis technologies are adapted to our research screening for rare driver genomic alterations of lung cancer, such as RET, ROS1, BRAF, MET, and HER2, etc., and its clinical development is also supported by collaborating with some diagnostic companies.
Clinical Trials
The Department of Thoracic Oncology is currently conducting and participating in multi-institutional clinical studies for the advanced lung cancer disease, such as the Japan Clinical Oncology Group (JCOG) trials, investigator-initiated trials, and pharmaceutical company-initiated global trials.
A genomic screening platform in Japan established by our department, LC-SCRUM-Asia, was initiated in 2013 and is now ongoing. As of March 2024, 142 Japanese institutions participated in LC-SCRUM-Japan, and 19,458 patients were enrolled. In addition, Asia-Pacific international genomic screening with Taiwan, Thailand, and Malaysia, named LC-SCRUM-AP, was initiated in January 2023 and is now ongoing. As of March 2024, 254 patients were already enrolled, and the project aims to promote precision medicine in Asia-Pacific countries. LC-SCRUM-Asia will support the development of novel therapeutic and diagnostic products and contribute to establishing precision medicine in Asian countries. Many lung cancers with rare driver oncogenes, such as RET, ROS1 BRAF, MET, HER2 NTRK, and KRAS G12C genomic alterations, were identified in our screening and entered into various clinical trials of molecular targeting agents. Based on the results of clinical trials leveraging genomic screening in LC-SCRUM-Asia, crizotinib was approved for ROS1 fusion-positive lung cancer in May 2017, dabrafenib/trametinib was approved for BRAF V600E mutation-positive lung cancer in March 2018, entrectinib was approved for NTRK and ROS1 fusion-positive lung cancer in June 2019 and February 2020, respectively, and tepotinib and capmatinib were approved for MET ex14 skipping positive lung cancer in March 2020 and June 2020, respectively. In addition, selpercatinib was approved for RET fusion-positive lung cancer in September 2021, and sotorasib was approved for KRAS G12C mutation-positive lung cancer in January 2022. This fiscal year, trastuzumab deruxtecan (T-DXd) was approved for the treatment of HER2 mutation-positive lung cancer in August 2023, making LC-SCRUM-Asia a significant achievement in the development of treatments for lung cancers with rare driver oncogenes.
The RT-PCR kit, which was adopted in LC-SCRUM-Asia screening for ROS1 fusion, was simultaneously approved using our screening data as a companion diagnostic (CDx) for ROS1-positive lung cancer in January 2017. In the same way, the next-generation sequencing (NGS) panel, Oncomine® DxTT, was first approved as a CDx for BRAF mutation-positive lung cancer in April 2018, and this is an important step forward in the clinical application of NGS multi-diagnostics. Oncomine® DxTT finally became an NGS multi CDx for six gene changes: EGFR/ALK/ROS1/BRAF/RET/HER2 in May 2023, significantly contributing to the development of precision medicine in lung cancer. In addition, the multi-PCR panel, AmoyDx® Pan Lung Cancer PCR Panel, with a short turnaround time, was approved as a multi CDx for EGFR/ALK/ROS1/BRAF/MET/RET/KRAS in March 2023. As a result, we can obtain the results of multi-genomic analysis within a week and start precision medicine for lung cancer from first-line treatment in clinical practice. Through genomic screening and establishing a clinical-genomic database, LC-SCRUM-Asia can be crucial in developing precision medicine for lung cancer in Japan and other Asian countries.
In addition to the targeted genomic screening, to identify some novel oncogenic driver genes, we initiated whole-transcriptome sequencing (WTS) of NSCLC samples negative for known oncogenic drivers in the LC-SCRUM-Asia from October 2020. In the WTS, we identified an in-frame fusion transcript of CLIP1 on chromosome 12q24 and LTK on chromosome 15q15 in one patient. The CLIP1-LTK fusion was present in 0.4% of NSCLCs and mutually exclusive to other known oncogenic drivers. We showed that the kinase activity of the CLIP1-LTK fusion protein was constitutively activated and had transformation potential. In vitro and in vivo analysis, the treatment with lorlatinib, an ALK inhibitor, inhibited CLIP1-LTK kinase activity, suppressed proliferation, and induced apoptosis. One patient with NSCLC harboring the CLIP1-LTK fusion showed an excellent clinical response to lorlatinib. This was the first description of LTK alterations with oncogenic activity in cancers, which was published in Nature in November 2021. Moreover, we started an investigator-initiated trial of lorlatinib for CLIP1-LTK fusion-positive lung cancer in February 2023.
We also initiated an additional genomic screening project for pre-treated patients to identify resistant genomic alterations after treatment with molecular targeting agents (LC-SCRUM-TRY) in September 2020. A total of 1,601 pre-treated patients were already enrolled in LC-SCRUM-TRY as of March 2024. We challenge the establishment of precision medicine according to the resistance mechanism to previous treatments by leveraging genomic screening of LC-SCRUM-TRY. Additionally, we started a new genomic screening project (LC-SCRUM-Advantage/MRD) for patients with stage I-III lung cancers who received surgical resection in August 2022 to establish precision medicine during perioperative treatment and clarify the clinical significance of micro residual disease (MRD) in blood samples. A total of 307 patients were already enrolled in LC-SCRUM-Advantage/MRD as of March 2024.
To select the optimal treatment for individual patients with advanced lung cancer, we currently need to identify genomic alterations by genomic tests and perform PD-L1 immunohistochemical staining using tissue samples in clinical practice. Since we need to obtain as much tissue samples as possible by bronchoscopy for the biomarker analyses, we conduct a feasibility study of the cutting-edge trans-bronchial biopsy technique to evaluate its utility.
Education
Residents, cancer specialists in training, and staff are paired to provide outpatient/inpatient medical care and perform examinations. The aim is to develop clinicians who can provide comprehensive medical care for patients with thoracic malignant tumors, from diagnosis to treatment, including palliative care, by closely supporting patients with advanced lung cancer for whom a complete cure is difficult. Moreover, our department always tries to train specialists with outstanding minds and powerful mental and physical strengths to handle patient’s distress. Residents must rotate in the Department of Pathology during their training period and have opportunities to come into contact with basic research from this department. Furthermore, we actively support the preparation of manuscripts on basic and clinical research, aiming to develop clinicians capable of conducting clinical and translational research. In addition, two thoracic oncologists are affiliated with the Joint Graduate Program at Juntendo University and Jikei University, respectively, and two specialized researchers have been studying at Cornell University in the United States since September 2023 and MD Anderson Cancer Center in the United States since October 2023, respectively.
A joint case conference with the Department of Thoracic Surgery is held every Tuesday. A joint case conference with the Department of Radiation Oncology is held every Wednesday to determine treatment policies. A research conference is held monthly to discuss the progress and schedule of research with all members. A journal club with the Department of Thoracic Oncology is held every Monday, a journal club with the Department of Thoracic Surgery is held every Wednesday, a joint conference with the Departments of Thoracic Surgery and Pathology is held every Friday, and a chest X-ray reading meeting for local clinicians is held on the second Tuesday of each month. A chest X-ray reading meeting with the Katsushika Medical Association is held on the fourth Tuesday of each month.
Future Prospects
Drug therapy for lung cancer has significantly shifted to precision medicine, in which therapeutic drugs are selected based on biomarkers in individual patients. In addition, immune checkpoint inhibitors have markedly contributed to improving treatment outcomes in lung cancer as highly effective drugs with a different mechanism of action from conventional medications. Dramatic advances in these new therapies have significantly changed the treatment landscape for advanced lung cancer in the last few years, and treatment outcomes have also significantly improved. In our department, we plan to continue conducting various future research studies to establish precision medicine for lung cancer based on biomarkers. Additionally, Asian countries such as Taiwan, Thailand, Malaysia, and Vietnam are participating in LC-SCRUM-Asia, and we would like to establish a large-scale international genomic screening platform in Asia-Pacific countries. By leveraging this screening platform, treatment development for advanced lung cancer, which has attracted much attention worldwide, will be conducted, and the results will be released to the world. Moreover, we will continue to promote translational research, conduct innovative and advanced clinical trials that can link the results to clinical development, and pursue research to overcome advanced lung cancer.
List of papers published in 2023
Journal
1. Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses. Cancer communications (London, England), 44:287-293, 2024
2. Nishio M, Murakami S, Kawakami H, Okishio K, Tamiya M, Kobayashi H, Fujimoto D, Sugawara S, Kozuki T, Oya Y, Izumi H, Shiroyama T, Satouchi M, Yamamoto N, Kaname S, Matsuoka D, Otake Y, Takase T, Semba T, Azuma K. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications, 4:226-235, 2024
3. Yamamoto N, Satouchi M, Doi T, Fujiwara Y, Yanagitani N, Kawa Y, Yoh K, Leopold L, Munteanu M, Sawada T, Han S, Noguchi K, Nishio M. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer. Investigational new drugs, 42:261-271, 2024
4. Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Taniguchi Y, Nosaki K, Fukumitsu K, Akechi T. Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer. The oncologist, 29:e282-e289, 2024
5. Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. Journal of thoracic oncology, 19:106-118, 2024
6. Tabata S, Umemura S, Narita M, Udagawa H, Ishikawa T, Tsuboi M, Goto K, Ishii G, Tsuchihara K, Ochiai A, Kobayashi SS, Soga T, Makinoshima H. Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma. Molecular cancer research, 22:82-93, 2024
7. Kitagawa S, Zenke Y, Taki T, Aokage K, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation. Lung cancer (Amsterdam, Netherlands), 188:107453, 2024
8. Cho BC, Chiu CH, Massarelli E, Buchschacher GL, Goto K, Overbeck TR, Loong HHF, Chee CE, Garrido P, Dong X, Fan Y, Lu S, Schwemmers S, Bordogna W, Zeuner H, Osborne S, John T. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 188:107442, 2024
9. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine, 390:118-131, 2024
10. Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. The Journal of experimental medicine, 221:e20232028, 2024
11. Nogami N, Tokito T, Zenke Y, Satouchi M, Seto T, Saka H, Ohtani J, Han S, Noguchi K, Nishio M. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer. Investigational new drugs, 42:136-144, 2024
12. Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future oncology (London, England), 2024
13. Tsukita Y, Taguri M, Goto Y, Hosomi Y, Mizutani T, Watanabe K, Yoh K, Takahashi S, Kubota K, Kunitoh H. Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial). Japanese journal of clinical oncology, 54:730-734, 2024
14. Sakurai H, Goto Y, Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Yoshida K, Ohde Y, Okumura S, Taguri M, Kunitoh H. Prognostic significance of ground-glass areas within tumours in non-small-cell lung cancer . European journal of cardio-thoracic surgery, 65:ezae158 , 2024
15. Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung cancer (Amsterdam, Netherlands), 181:107195, 2023
16. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Song B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Funderburk KM, Li S, Zhang T, Breeze C, Wang Z, Blechter B, Bassig BA, Kim JH, Albanes D, Wong JYY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Ho JCM, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood DH, Kunitoh H, Patel H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Lee VHF, Chang GC, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, Schwartz AG, Houlston R, Spitz MR, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold S, Brennan P, McKay J, Field JK, Shete SS, Le Marchand L, Liu G, Andrew A, Kiemeney LA, Zienolddiny-Narui S, Grankvist K, Johansson M, Cox A, Taylor F, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Jeon HS, Jiang SS, Sung JS, Chen CH, Hsiao CF, Jung YJ, Guo H, Hu Z, Burdett L, Yeager M, Hutchinson A, Hicks B, Liu J, Zhu B, Berndt SI, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Wang WC, Xu J, Guan P, Tan W, Yu CJ, Yang G, Sihoe ADL, Chen Y, Choi YY, Kim JS, Yoon HI, Park IK, Xu P, He Q, Wang CL, Hung HH, Vermeulen RCH, Cheng I, Wu J, Lim WY, Tsai FY, Chan JKC, Li J, Chen H, Lin HC, Jin L, Liu J, Sawada N, Yamaji T, Wyatt K, Li SA, Ma H, Zhu M, Wang Z, Cheng S, Li X, Ren Y, Chao A, Iwasaki M, Zhu J, Jiang G, Fei K, Wu G, Chen CY, Chen CJ, Yang PC, Yu J, Stevens VL, Fraumeni JF Jr, Chatterjee N, Gorlova OY, Hsiung CA, Amos CI, Shen H, Chanock SJ,. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nature communications, 14:3043, 2023
17. Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, Hirashima T, Tanaka H, Fukuhara T, Nakahara Y, Kurata T, Katakami N, Okada M, Horinouchi H, Udagawa H, Kasahara K, Satouchi M, Saka H, Tokito T, Hosomi Y, Aoe K, Kishi K, Ohashi K, Yokoyama T, Adachi N, Noguchi K, Schwarzenberger P, Kato T. Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer science, 114:3330-3341, 2023
18. Yoshida T, Kumagai T, Toyozawa R, Katayama R, Nishio M, Seto T, Goto K, Yamamoto N, Ohe Y, Kudou K, Asato T, Zhang P, Nakagawa K. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science, 114:3698-3707, 2023
19. Kunimasa K, Matsumoto S, Honma K, Tamiya M, Inoue T, Kawamura T, Tanada S, Miyazaki A, Kanzaki R, Maniwa T, Okami J, Matsumoto Y, Goto K, Nishino K. Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study. BMC pulmonary medicine, 23:484, 2023
20. Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight. Cancer science, 114:2087-2097, 2023
21. Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. Journal of clinical oncology, 41:4678-4687, 2023
22. Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K. Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR(+)non-small-cell lung cancer. Translational lung cancer research, 12:1167-1184, 2023
23. Ohtani-Kim SJ, Taki T, Tane K, Miyoshi T, Samejima J, Aokage K, Nagasaki Y, Kojima M, Sakashita S, Watanabe R, Sakamoto N, Goto K, Tsuboi M, Ishii G. Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma. Modern pathology, 36:100209, 2023
24. Tanaka T, Umemura S, Miyoshi T, Nakai T, Noritake O, Suzuki J, Tane K, Samejima J, Aokage K, Mimaki S, Tsuchihara K, Taki T, Miyazaki S, Watanabe R, Sakashita S, Sakamoto N, Kojima M, Goto K, Ikeda N, Tsuboi M, Ishii G. The prognostic impact of a high number of peritumoral alveolar macrophages in neuroendocrine carcinoma in the lung. Pathology international, 73:497-508, 2023
25. Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Clinical cancer research , 29:1506-1514, 2023
26. Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. Journal of clinical oncology, 41:2893-2903, 2023
27. Tanaka Y, Nakai T, Suzuki A, Kagawa Y, Noritake O, Taki T, Hashimoto H, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanbe R, Tsuboi M, Goto K, Ishii G. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. Cancer immunology, immunotherapy, 72:2205-2215, 2023
28. Shiraishi T, Yamasaki K, Kidogawa M, Shingu T, Ujimiya F, Jotatsu T, Matsumoto S, Izumi H, Nishida C, Goto K, Yatera K. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene. Internal medicine (Tokyo, Japan), 62:3215-3221, 2023
29. Kunimasa K, Matsumoto S, Kawamura T, Inoue T, Tamiya M, Kanzaki R, Maniwa T, Okami J, Honma K, Goto K, Nishino K. Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung cancer (Amsterdam, Netherlands), 179:107190, 2023
30. Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, Zhang L, Bai C, Fang J, Cao L, Zhao Y, Yu Y, Shi M, Zhong D, Li F, Li M, Wu Q, Zhou J, Sun M, Lu S. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial. EClinicalMedicine, 59:101952, 2023
31. Kagawa Y, Nakai T, Taki T, Hashimoto H, Tanaka Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Watanabe R, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Goto K, Ishii G. Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma. Cancer science, 114:3423-3432, 2023
32. Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, Tanizaki J, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clinical lung cancer, 24:e247-e253, 2023
33. Oyoshi H, Hirata H, Hirano Y, Zenda S, Zhou Y, Tomizawa K, Fujisawa T, Nakamura M, Hojo H, Motegi A, Kageyama SI, Zenke Y, Goto K, Ishihara S, Naganawa S, Akimoto T. Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy. Clinical & experimental metastasis, 40:407-413, 2023
34. Sakai T, Matsumoto S, Ueda Y, Shibata Y, Ikeda T, Nakamura A, Kodani M, Ohashi K, Furuya N, Izumi H, Nosaki K, Umemura S, Zenke Y, Udagawa H, Sugiyama E, Yoh K, Goto K. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). Journal of thoracic oncology, 18:1538-1549, 2023
35. Ohtsu A, Goto K, Yoshino T. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 99:241-253, 2023
36. Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, Yanamoto S, Miyauchi M, Kajiya M. AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma. Oncogene, 42:2869-2877, 2023
37. Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Takahashi T, Tsuboi M. Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology, 41:5242-5246, 2023
38. Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology, 41:5363-5375, 2023
39. Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Jänne PA. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. Journal of clinical oncology, 41:4852-4863, 2023
40. Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical lung cancer, 24:641-650.e2, 2023
41. Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. The New England journal of medicine, 389:2063-2075, 2023
42. Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. The New England journal of medicine, 389:1839-1850, 2023
43. Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine, 66:102303, 2023